BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Addiction-stricken community struggles to keep a syringe program going after Trump's order - 2Warning for snow and ice extended
- 3Scientists discover black hole flare with the light of 10 trillion suns
- 4Vote In favor of Your #1 Compelling Female Producer
- 5The Oscars are moving from ABC to YouTube starting in 2029
- Lahav 433 head Asst.-Ch. Meni Benjamin named as police officer investigated for breach of trust
- IDF carried out mission to locate former hostage Avera Mengistu a day before Oct. 7
- Desired Travel Objections Worldwide: Where to Go Straightaway
- Explainer-What has happened to the damaged spacecraft at China's space station?
- Flu illness count nears 5 million, with New York City among the hardest hit
- Hezbollah rockets hit 165 UNIFIL positions in Lebanon while targeting Israel, IDF reveals
- Gulf countries roll out more autonomous taxis
- VPN Administrations for Online Protection
- This Week In Space podcast: Episode 204 — A New NASA
